Faced with stress and brain fog, columnist Juliet Taylor thought that staying on top of things would keep her husband's ALS ...

The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...

Clene is scheduled to meet with the FDA in the coming months to discuss new data for CNM-Au8, its experimental oral therapy ...

Shionogi plans to acquire global rights to Radicava and Radicava ORS for ALS through a new U.S. business formed by Tanabe ...

The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

The ALS Association is urging members of Congress to take action to address issues with instability in leadership at the NIH.

Health Canada has cleared the way for ALS patients in that nation to join the ongoing ALSTARS U.S. trial testing therapy ...

Even after 15 years with her husband's ALS, losing caregivers still brings about grief and stress for columnist Kristin Neva.

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

For columnist Dagmar Munn, using the momentum of "swingtime" is helping her manage ALS-related stress and get through tasks.

QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...